Limited pharmacological treatments for uterine leiomyomata (fibroids) are available. Now, two phase III trials lasting 24 weeks showed marked reduction in leiomyoma-related heavy menstrual bleeding with relugolix, a new orally active gonadotropin-releasing hormone antagonist with add-back oestrogen (to limit bone loss) and progestin (to limit endometrial changes from unopposed oestrogen).
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stewart, E. A. et al. Uterine fibroids. Nat. Rev. Dis. Primers 2, 16043 (2016).
ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet. Gynecol. 112, 387–400 (2008).
Al-Hendy, A. et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N. Engl. J. Med. 384, 630–642 (2021).
Lewis, T. D., Malik, M., Britten, J., San Pablo, A. M. & Catherino, W. H. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed. Res. Int. 2018, 2414609 (2018).
Farris, M., Bastianelli, C., Rosato, E., Brosens, I. & Benagiano, G. Uterine fibroids: an update on current and emerging medical treatment options. Ther. Clin. Risk Manag. 15, 157–178 (2019).
Mozzanega, B. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. J. Hepatol. 74, 750–751 (2021).
Ciebiera, M. et al. The evolving role of natural compounds in the medical treatment of uterine fibroids. J. Clin. Med. 9 (2020).
Baird, D. D., Saldana, T. M., Shore, D. L., Hill, M. C. & Schectman, J. M. A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years. Hum. Reprod. 30, 2936–2944 (2015).
Flake, G. P. et al. The natural history of uterine leiomyomas: light and electron microscopic studies of fibroid phases, interstitial ischemia, inanosis, and reclamation. Obstet. Gynecol. Int. 2013, 528376 (2013).
Baird, D. D. et al. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am. J. Obstet. Gynecol. 223, 402 (2020).
The authors thank L. Wyrick and T. Winslow for assistance with figure creation and A. Wilcox for reviewing the figure format. E. Myers read and commented on an earlier version of the text. The authors also acknowledge the support of the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences.
The authors declare no competing interests.
About this article
Cite this article
Baird, D.D., Harmon, Q.E. Relugolix — new treatment for uterine fibroid-related heavy bleeding. Nat Rev Endocrinol 17, 321–322 (2021). https://doi.org/10.1038/s41574-021-00493-2